EUVIMEDEUVIMED entdecken
Crossref

Mosunetuzumab (Lunsumio) for Follicular Lymphoma

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1671f ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antibodies, Bispecific, Antineoplastic Agents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mosunetuzumab-axgb (Lunsumio – Genentech), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for treatment of relapsed or refractory follicular lymphoma in adults who received ≥2 lines of systemic therapy. It is the first T-cell-engaging bispecific antibody to be approved in the US for this indication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularAntibodies, BispecificAntineoplastic AgentsHumans

Stichwörter der Autor:innen

AliqopaGazyvaKymriahLunsumioYescartaZydeligadverse effectsaxicabtagene ciloleucelcopanlisibdosagedrug interactionsefficacyidelasiliblactationlymphoma

Substanzen

Antibodies, BispecificAntineoplastic Agents

Zitieren

APA

(2023). Mosunetuzumab (Lunsumio) for Follicular Lymphoma. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1671f

Vancouver

Mosunetuzumab (Lunsumio) for Follicular Lymphoma. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1671f

BibTeX
@article{euvimed2023,
  title = {Mosunetuzumab (Lunsumio) for Follicular Lymphoma},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1671f}
}
Kostenlos starten →